Pathogenesis: Abnormal Uterine Bleeding (AUB)
Key Points
Text
I. Introduction
A. Prevalence and significance of leiomyomas in patients with abnormal uterine bleeding (AUB)
II. Role of Vasoactive Growth Factors
A. Secretion of vasoactive growth factors by leiomyomas
B. Abnormal expression of growth factors (bFGF, EGF, VEGF, PDGF, IGF-1, TGF-β, PTHrP, prolactin) in leiomyomas
C. Induction of angiogenesis and vasculogenesis in the endometrium
D. Impact on blood vessel proliferation and abnormal hemostasis mechanisms
III. Coagulation Cascade and Thrombolytic Factors
A. Decreased expression of hemostatic factors (PAI-1, TM) in the endometrium
B. Role of TGF-β3 in influencing coagulation/anticoagulation mechanisms
C. Implications for leiomyoma-associated abnormal bleeding
IV. Proximity to the Endometrium
A. Distortion of the endometrial cavity caused by leiomyoma location
B. Hypothesis for leiomyomas contributing to AUB based on proximity to the endometrium
C. Impact of submucous leiomyomas on endometrial hemostasis
V. Therapeutic Implications
A. Importance of understanding the underlying mechanisms for developing targeted treatments
B. Potential therapeutic targets based on the pathogenesis of abnormal uterine bleeding
FIGO HQ
FIGO House,
Suite 3, Waterloo Court,
10 Theed Street,
London SE1 8ST, UK